ANVS Annovis Bio
- 5.930
- -0.100-1.66%
- 6.100
- +0.170+2.87%
Annovis Bio News
Annovis Bio | 10-Q: Quarterly report
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
Thu, 09 May 2024MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neur
Annovis Bio Issues Key Update on Corporate Progress
Annovis Bio CEO Outlines Next Steps in Alzheimer's Research After Mixed Phase II/III Trial Results
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder,
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Mon, 06 May 2024MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neur
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
Annovis Bio CFO Henry Hagopian Resigns, CEO Steps In
BKKT, CETX and SWVL Among Mid-day Movers
Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals Among Healthcare Movers
Annovis Bio Is Maintained at Buy by Canaccord Genuity
Annovis Bio Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $26
Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio with a Buy and lowers the price target from $36 to $26.
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
HC Wainwright & Co. : The Annovis Bio (ANVS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $30.00.
HC Wainwright & Co. : The Annovis Bio (ANVS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $30.00.
HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio with a Buy and maintains $30 price target.
Annovis Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 320.76% HC Wainwright & Co. → $30 Reiterates Buy → Buy 04/02/2024 320.76% HC Wainwright & Co. $
Daily ticket tracking | Tesla earns 48x in a single call! The bullish ratio has been rising for four consecutive days
Apple's premium for multiple calls due on Friday doubled; Amazon's previous sales of multiple call orders were stolen. Among them, the volume of calls due on Friday and with an exercise price of 190/200 US dollars all exceeded 20,000.
Top Midday Decliners
Clever Leaves (CLVR) shares slumped nearly 61% in recent trading Monday. The company disclosed Friday its board decided to delist its securities on Nasdaq. ,Intraday trading volume was over 701,000 ve
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 0.1% on Monday.The Dow traded up 0.19% to 38,313.56 while the NASDAQ rose 0.13% to 15,948.81. The S&P 500
Trending Stocks Today: Collective Audience Soars 80.76%
April 29th - US stocks trending in regular trading hours.Gainers: $Collective Audience(CAUD.US)$ shoots up 80.76% to $0.71 with a turnover of $102.48 million. $Deciphera Pharmaceuticals(DCPH.US)$ soar
Why Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday?
Annovis Bio Inc (NASDAQ:ANVS) shares plunged after the company released data from its Phase 2/3 Alzheimer study of buntanetap in mild to moderate Alzheimer's patients. Investors are reacting as during
Analysis
Price Target
No Data
